Risks and Alternatives to Long-Term Metoclopramide Use
Risks of Long-Term Metoclopramide Use
- Extrapyramidal symptoms including acute dystonic reactions, drug-induced parkinsonism, and akathisia can occur in patients taking metoclopramide, according to the American Diabetes Association, as reported in Diabetes Care 1
Recommended Alternative Treatments
- Domperidone, a peripheral D2 dopamine receptor antagonist, is a recommended alternative treatment for patients with gastroparesis, as suggested by the European Society of Gastrointestinal Motility, and requires QTc monitoring, as reported in Gut 2
- Erythromycin, a motilin agonist, can improve gastric emptying in patients with gastroparesis, but is subject to tachyphylaxis, limiting its use to short-term treatment, as reported in Gut 2
- Prucalopride, a selective 5-HT4 receptor agonist, is a recommended treatment for constipation without the cardiac risks of older prokinetics, as reported in Gut 2
- Azithromycin may be more effective than erythromycin for small bowel dysmotility, as reported in Gut 2
- Octreotide, a somatostatin analogue, may be beneficial for patients with systemic sclerosis, administered subcutaneously, as reported in Gut 2
Non-Pharmacological Approaches
- A low-fiber, low-fat eating plan with small, frequent meals and a higher proportion of liquid calories, as well as foods with small particle size, is a recommended dietary modification for patients with gastroparesis, as suggested by the American Diabetes Association, as reported in Diabetes Care 1 and 3
- Gastric electrical stimulation, a surgically implantable device, may be considered for severe, refractory cases of gastroparesis, although efficacy is variable, as reported in Diabetes Care 1 and 3
Management Recommendations
- Patients with diabetes require careful monitoring as gastroparesis may affect glycemic control, as reported in Diabetes Care 1
- Monitoring for worsening of underlying condition, such as gastroparesis, during medication changes is crucial, as reported in Diabetes Care 1
- Monitoring for improvement in existing neurological symptoms after discontinuation of metoclopramide is necessary, as reported in Gut 2